Clinical Trials Browser

Neoplasms × lenvatinib × Gastrointestinal × Clear all

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05822752 2025-08-14

LIVIGNO-1

Phase 2 Active not recruiting

130 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT05620134 2024-10-15

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Phase 1/2 Active not recruiting

263 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04519151 2023-06-08

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

Phase 2 Recruiting

24 enrolled

GastrointestinalGynecologic

NCT05322187 2022-04-11

sPLENTY-pc

Phase 2/3 Unknown

15 enrolled

Gastrointestinal

Liver Neoplasms, Neoplasms, Hepatoblastoma

NCT01761266 2022-04-05

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

Phase 3 Completed

954 enrolled 19 charts 2 FDA

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT04008082 2022-03-08

A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma

Completed

412 enrolled

Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular, Neoplasms, Neoplasms, Glandular and Epithelial

Clinical Trials

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

LIVIGNO-1

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

sPLENTY-pc

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma